ESSA Net Working Capital vs Accounts Payable Analysis

EPIX Stock  USD 1.79  0.02  1.10%   
ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Net Working Capital and its Accounts Payable accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

Net Working Capital vs Accounts Payable

Net Working Capital vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Net Working Capital account and Accounts Payable. At this time, the significance of the direction appears to have very week relationship.
The correlation between ESSA Pharma's Net Working Capital and Accounts Payable is 0.24. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Net Working Capital and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of ESSA Pharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Working Capital i.e., ESSA Pharma's Net Working Capital and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.24
Relationship DirectionPositive 
Relationship StrengthVery Weak

Net Working Capital

Accounts Payable

An accounting item on the balance sheet that represents ESSA Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ESSA Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Selling General Administrative is likely to drop to about 7.5 M in 2024. Tax Provision is likely to drop to 1,368 in 2024

ESSA Pharma fundamental ratios Correlations

0.590.371.0-0.75-0.950.270.760.290.490.930.440.9-0.031.00.010.99-0.291.00.820.59-0.150.950.630.610.97
0.590.020.6-0.83-0.43-0.080.810.210.390.380.620.4-0.170.59-0.070.48-0.180.530.310.29-0.050.410.560.690.46
0.370.020.34-0.37-0.430.720.40.540.180.430.570.280.720.370.260.370.160.350.360.580.150.310.580.450.31
1.00.60.34-0.75-0.940.240.760.270.470.930.420.89-0.071.00.00.98-0.311.00.820.57-0.150.950.620.60.98
-0.75-0.83-0.37-0.750.57-0.12-1.0-0.23-0.3-0.7-0.63-0.480.02-0.750.05-0.640.21-0.7-0.65-0.430.07-0.55-0.76-0.72-0.59
-0.95-0.43-0.43-0.940.57-0.35-0.6-0.27-0.56-0.87-0.37-0.93-0.07-0.95-0.04-0.970.26-0.95-0.72-0.670.18-0.93-0.58-0.45-0.97
0.27-0.080.720.24-0.12-0.350.140.440.490.320.510.260.720.270.260.30.630.260.30.220.220.280.460.430.26
0.760.810.40.76-1.0-0.60.140.250.310.720.630.510.010.76-0.050.66-0.220.710.660.48-0.080.570.780.720.61
0.290.210.540.27-0.23-0.270.440.250.360.260.440.270.520.290.670.280.120.250.340.350.20.350.120.620.23
0.490.390.180.47-0.3-0.560.490.310.360.430.380.590.420.490.070.520.330.470.40.41-0.230.480.250.440.51
0.930.380.430.93-0.7-0.870.320.720.260.430.330.840.030.930.030.93-0.260.940.950.56-0.140.90.580.530.91
0.440.620.570.42-0.63-0.370.510.630.440.380.330.340.460.450.110.380.120.380.240.520.310.270.780.810.33
0.90.40.280.89-0.48-0.930.260.510.270.590.840.340.030.90.050.94-0.310.910.730.7-0.250.90.470.410.95
-0.03-0.170.72-0.070.02-0.070.720.010.520.420.030.460.03-0.030.220.00.55-0.060.030.42-0.05-0.030.160.3-0.06
1.00.590.371.0-0.75-0.950.270.760.290.490.930.450.9-0.030.010.99-0.291.00.820.59-0.150.950.630.610.97
0.01-0.070.260.00.05-0.040.26-0.050.670.070.030.110.050.220.010.030.20.010.030.020.160.030.030.10.02
0.990.480.370.98-0.64-0.970.30.660.280.520.930.380.940.00.990.03-0.280.990.810.61-0.160.970.570.541.0
-0.29-0.180.16-0.310.210.260.63-0.220.120.33-0.260.12-0.310.55-0.290.2-0.28-0.31-0.22-0.40.0-0.26-0.070.09-0.3
1.00.530.351.0-0.7-0.950.260.710.250.470.940.380.91-0.061.00.010.99-0.310.830.57-0.150.960.590.550.99
0.820.310.360.82-0.65-0.720.30.660.340.40.950.240.730.030.820.030.81-0.220.830.42-0.090.840.430.560.78
0.590.290.580.57-0.43-0.670.220.480.350.410.560.520.70.420.590.020.61-0.40.570.42-0.240.50.510.330.59
-0.15-0.050.15-0.150.070.180.22-0.080.2-0.23-0.140.31-0.25-0.05-0.150.16-0.160.0-0.15-0.09-0.24-0.160.180.31-0.18
0.950.410.310.95-0.55-0.930.280.570.350.480.90.270.9-0.030.950.030.97-0.260.960.840.5-0.160.40.540.96
0.630.560.580.62-0.76-0.580.460.780.120.250.580.780.470.160.630.030.57-0.070.590.430.510.180.40.550.53
0.610.690.450.6-0.72-0.450.430.720.620.440.530.810.410.30.610.10.540.090.550.560.330.310.540.550.47
0.970.460.310.98-0.59-0.970.260.610.230.510.910.330.95-0.060.970.021.0-0.30.990.780.59-0.180.960.530.47
Click cells to compare fundamentals

ESSA Pharma Account Relationship Matchups

ESSA Pharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets80.6M198.2M169.5M149.1M171.5M180.1M
Other Current Liab24.2M39.2M36.4M1.4M1.6M1.5M
Total Current Liabilities1.2M3.9M2.3M3.5M4.0M3.0M
Total Stockholder Equity79.2M194.0M167.1M145.6M167.5M175.8M
Net Debt(56.3M)(137.5M)(56.9M)(33.6M)(30.3M)(31.8M)
Retained Earnings(81.0M)(117.8M)(152.9M)(179.5M)(161.5M)(153.4M)
Accounts Payable678.6K1.4M954.6K2.0M2.3M1.4M
Cash56.3M137.8M57.1M33.7M38.8M34.1M
Non Current Assets Total55.2K567.7K446.0K325.3K374.0K383.8K
Non Currrent Assets Other(200.7K)277.6K259.5K257.2K295.8K181.3K
Cash And Short Term Investments56.3M194.9M57.1M148.1M170.3M178.8M
Other Current Assets1.7M2.2M1.8M585.4K673.2K1.2M
Other Stockholder Equity31.2M36.4M44.0M49.0M56.4M59.2M
Total Liab1.3M4.2M2.4M3.5M4.0M4.6M
Total Current Assets80.6M197.6M169.5M148.8M171.1M179.7M
Common Stock131.1M277.4M278.1M278.2M319.9M335.9M
Other Liab19.6K16.5K127.4K20.4K18.3K17.4K
Net Tangible Assets49.0M79.2M194.0M167.1M192.2M201.8M
Other Assets(55.2K)198.2M(446.0K)115.4M132.7M139.3M
Net Receivables309.5K489.0K6.2K135.1K121.6K115.5K
Liabilities And Stockholders Equity80.6M198.2M169.5M149.1M171.5M180.1M
Inventory420.5K(360.8K)(309.5K)110.6M127.2M133.6M
Short Term Debt59.1K120.7K133.8K80.3K92.4K87.8K
Common Stock Shares Outstanding22.4M38.5M44.0M44.1M50.7M53.2M
Non Current Liabilities Total127K230.6K77K(71.0)(63.9)(60.7)
Short Long Term Debt Total59.1K331.0K209.8K80.3K72.3K68.7K
Net Invested Capital79.2M194.0M167.1M145.6M167.5M103.4M
Net Working Capital79.1M193.7M166.7M145.3M167.1M101.6M
Capital Stock131.1M277.4M278.1M278.2M319.9M198.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.